PRODUCTS & INNOVATION
SMALL TECH, BIG IMPACT
New data reinforce Abbott’s leadership in minimally invasive structural heart therapies.
Jul 20 2020
Abbott has rolled out a slew of new data on five of its life-changing structural heart technologies, including the MitraClip system* (repairs a leaky mitral valve) the Amplatzer Amulet LAA Occluder** (designed to help reduce stroke risk in people with atrial fibrillation) and the PorticoTM with FlexNavTM transcatheter aortic valve replacement system** (replaces a diseased or damaged aortic valve).
Get the details on these findings, which reinforce Abbott’s position as a leader in minimally invasive structural heart treatments.
*For U.S. important safety information on MitraClip, visit: https://mitraclip.com/fileadmin/isi/AP2948066-US-MitraClip-G4_CDS_ISI_VP.pdf
**These products are available commercially in the EU and are in clinical trials in the United States.
Freestyle Libre 2: Next-Gen CGM is Here
FreeStyle Libre System Poised for Broader Reach
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.